Full Text View
Tabular View
No Study Results Posted
Related Studies
Clinical Trial of L-Grb-2 Antisense Oligonucleotide in CML, AML, ALL & MDS
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by Bio-Path Holdings, Inc..
Recruitment status was  Recruiting
Study NCT01159028   Information provided by Bio-Path Holdings, Inc.

First Received on July 7, 2010.   Last Updated on July 8, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myelodysplastic Syndromes
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Bone Marrow Diseases
Chromosome Aberrations
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Leukemia
Leukemia, Lymphoid
Leukemia, Myeloid
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Translocation, Genetic
Interventions listed in this trial
BP-100-1.01 (Liposomal Grb-2)
Sponsors listed in this trial
Bio-Path Holdings, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services